AtriCure, Inc. (NASDAQ:ATRC) Given Average Rating of “Moderate Buy” by Analysts

Shares of AtriCure, Inc. (NASDAQ:ATRC) have been given an average recommendation of “Moderate Buy” by the eleven analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and ten have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $52.2222.

Several brokerages recently commented on ATRC. Wall Street Zen raised shares of AtriCure from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of AtriCure in a report on Wednesday, October 8th. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research note on Thursday, October 30th. BTIG Research set a $54.00 target price on shares of AtriCure in a report on Wednesday, July 30th. Finally, Needham & Company LLC boosted their price target on AtriCure from $44.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, July 30th.

AtriCure Trading Up 2.7%

Shares of ATRC stock opened at $32.86 on Wednesday. The business has a 50-day moving average of $35.37 and a 200 day moving average of $33.97. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.94 and a quick ratio of 2.83. AtriCure has a 1-year low of $28.29 and a 1-year high of $43.11. The stock has a market capitalization of $1.63 billion, a PE ratio of -53.87 and a beta of 1.56.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Wednesday, October 29th. The medical device company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.10. AtriCure had a negative return on equity of 2.56% and a negative net margin of 5.55%.The business had revenue of $134.27 million for the quarter, compared to analysts’ expectations of $131.25 million. During the same period in the previous year, the firm earned ($0.17) EPS. The business’s quarterly revenue was up 15.8% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. As a group, sell-side analysts anticipate that AtriCure will post -0.6 earnings per share for the current year.

Insider Activity at AtriCure

In related news, Director Sven Wehrwein sold 5,000 shares of AtriCure stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $37.00, for a total value of $185,000.00. Following the sale, the director owned 34,374 shares in the company, valued at $1,271,838. The trade was a 12.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Justin J. Noznesky sold 3,000 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $36.30, for a total transaction of $108,900.00. Following the transaction, the insider directly owned 83,964 shares in the company, valued at approximately $3,047,893.20. The trade was a 3.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 13,000 shares of company stock worth $473,900 over the last three months. Insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On AtriCure

A number of large investors have recently modified their holdings of the stock. Acadian Asset Management LLC grew its holdings in shares of AtriCure by 2,690.0% during the 1st quarter. Acadian Asset Management LLC now owns 195,582 shares of the medical device company’s stock worth $6,304,000 after acquiring an additional 188,572 shares during the period. First Bank & Trust bought a new stake in shares of AtriCure during the second quarter valued at approximately $273,000. Osterweis Capital Management Inc. bought a new stake in shares of AtriCure during the first quarter valued at approximately $9,536,000. Envestnet Asset Management Inc. grew its stake in AtriCure by 22.9% in the first quarter. Envestnet Asset Management Inc. now owns 56,656 shares of the medical device company’s stock worth $1,828,000 after purchasing an additional 10,570 shares during the period. Finally, Cresset Asset Management LLC bought a new position in AtriCure in the first quarter worth $365,000. Institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.